editor
longact
suspens
buprenorphin
may
combin
manag
medic
approach
reduc
advers
effect
associ
buprenorphin
analgesia
extendedreleas
drug
reduc
anim
exposur
cycl
hyper
hypotherapeut
drug
level
also
reduc
opportun
iatrogen
injuri
associ
effort
secur
small
anim
repeat
drug
inject
singl
inject
drug
provid
anim
two
three
day
analges
therapi
given
anim
still
postsurg
anesthesia
howev
effect
longact
buprenorphin
analges
risk
nausea
rat
remain
uncertain
previous
conduct
target
anim
safeti
ta
test
lipidbound
extendedreleas
buprenorphin
suspens
fischer
safeti
trial
new
veterinari
pharmaceut
product
requir
clinic
histopatholog
studi
male
femal
anim
given
tenfold
excess
dose
drug
test
includ
trial
use
singl
inject
increas
concentr
buprenorphin
three
repeat
inject
fourday
interv
increas
concentr
buprenorphin
test
includ
blind
behavior
observ
monitor
unexpect
sign
stress
pain
avoid
use
hardwood
bed
nauseainduc
gastric
distress
pica
expect
find
signific
weight
loss
howev
observ
nausearel
behavior
consist
excess
selflick
gnaw
singl
repeat
doseescal
trial
object
studi
measur
incid
durat
characterist
nausea
behavior
rat
treat
extendedreleas
buprenorphin
analges
maintain
soft
fiber
bed
monitor
sign
nausea
trial
use
femal
fischer
rat
weigh
g
obtain
tacon
farm
hudson
ny
studi
use
three
group
six
rat
two
group
drugtreat
rat
one
group
drugfre
vehicl
control
investig
effect
drug
nausearel
behavior
sign
guidelin
ta
studi
specifi
minimum
number
three
anim
per
group
four
rat
use
ta
studi
account
potenti
morbid
jugular
vein
phlebotomi
limit
inform
side
effect
nausea
associ
extendedreleas
buprenorphin
use
six
rat
per
group
present
test
increas
potenti
observ
side
effect
rat
hous
environmentallycontrol
room
maintain
f
rel
humid
dark
cycl
rat
hous
two
three
per
cage
quarantin
acclim
period
ventil
micro
isol
cage
hous
two
per
cage
studi
period
cage
chang
daili
first
seven
day
studi
prevent
redos
coprophagi
carefresh
natur
bed
ferndal
wa
use
absorb
liquid
rat
provid
ad
libitum
access
drink
water
baltimor
citi
water
system
baltimor
md
harlan
teklad
certifi
global
rodent
diet
harlan
teklad
indianapoli
health
surveil
conduct
soiledbed
sentinel
system
rat
consid
neg
pneumonia
viru
mice
reoviru
sendai
viru
lymphocyt
choriomening
viru
rat
coronaviru
sialodacryoaden
viru
rat
parvoviru
kilham
rat
viru
toolan
parvoviru
rat
theiloviru
ciliaassoci
respiratori
bacillu
pneumocysti
carinii
mycoplasma
pulmoni
pinworm
rat
quarantin
acclim
six
day
dose
clinic
veterinarian
approv
anim
studi
use
rat
appear
normal
sign
diseas
anim
weigh
assign
dose
group
assur
weight
rat
within
group
averag
order
dose
start
mgkg
group
end
vehicl
control
group
rat
given
vehicl
control
mgkg
buprenorphin
intend
dose
mgkg
buprenorphin
twofold
excess
dose
mgkg
buprenorphin
control
suspens
consist
cholesterol
glycerol
tristear
suspend
mediumchain
triglycerid
oil
ul
drug
suspens
consist
buprenorphin
cholesterol
glycerol
tristear
trade
name
animalges
mice
suppli
animalges
lab
millersvil
md
procedur
done
ventil
hood
anim
room
contain
rat
cage
eas
use
histori
safeti
laboratori
anesthet
rat
ml
intraperiton
ip
solut
contain
mgml
ketamin
hydrochlorid
mgml
xylazin
ethyl
alcohol
salin
approxim
inject
rat
subcutan
design
dose
test
articl
buprenorphinefre
control
suspens
middors
area
use
g
needl
attach
ml
syring
rat
anesthet
dose
approxim
min
follow
dose
administr
transfer
rat
recoveri
cage
heat
pad
recov
anim
regain
conscious
demonstr
normal
movement
absenc
sign
distress
return
home
cage
tail
anim
mark
sharpi
pen
denot
anim
number
group
first
week
studi
anim
observ
cage
level
daili
approxim
morbid
mortal
sign
toxic
abnorm
respir
tremor
ocular
discharg
facial
sign
postur
movement
overal
appear
rat
receiv
handson
detail
clinic
observ
daili
pm
abnorm
clinic
sign
ocular
discharg
motor
activ
sign
pain
distress
etc
paw
gnaw
excess
groom
score
yesno
basi
rat
observ
weekli
thereaft
observ
femal
veterinarian
blind
treatment
group
experiment
unit
singl
anim
extend
baselin
data
nausearel
behavior
associ
buprenorphin
analgesia
compar
data
studi
result
rat
previou
two
ta
plasma
drug
concentr
report
collect
ta
rat
blood
sampl
obtain
technicianrestrain
unanesthet
anim
jugular
vein
phlebotomi
sampl
collect
h
drug
inject
zero
time
sampl
collect
h
rat
dose
drug
plasma
sampl
analyz
shimadzu
mass
spectromet
columbia
md
sensit
assay
observ
pica
present
studi
rat
surviv
predetermin
endpoint
studi
one
year
observ
abnorm
major
rat
treatment
group
exhibit
behavior
indic
nausea
either
morn
afternoon
observ
period
tabl
find
rat
dose
mgkg
lipidbound
buprenorphin
rat
dose
mgkg
drug
show
sign
nausea
includ
excess
groom
selfgnaw
time
nausea
onset
h
last
three
four
day
day
behavior
singl
affect
femal
intend
dose
group
unremark
day
five
behavior
two
affect
rat
higher
dose
group
also
within
normal
limit
blood
level
concentr
drug
poorli
correl
appear
nausea
sign
follow
singl
subcutan
sc
dose
mgkg
plasma
concentr
buprenorphin
rang
ngml
h
ngml
day
three
drug
level
group
dose
mgkg
rang
ngml
h
post
inject
ngml
day
three
opioid
bind
properti
buprenorphin
may
account
lack
coordin
nausea
sign
blood
concentr
drug
buprenorphin
plasma
concentr
greater
ngml
demonstr
clinic
relev
analgesia
laboratori
anim
despit
applic
blood
concentr
drug
least
three
day
plasma
level
buprenorphin
close
coupl
appear
durat
nausearel
behavior
data
conson
result
ta
studi
show
excess
groom
selfgnaw
forepaw
rat
singl
inject
trial
nausearel
behavior
seen
rat
second
trial
extendedreleas
buprenorphin
incid
behavior
highest
anim
receiv
mgkg
twice
intend
dose
onset
behavior
studi
gener
within
first
day
dose
yet
delay
onset
commonli
observ
present
studi
one
rat
exhibit
behavior
day
first
ta
trial
drugtreat
rat
exhibit
sign
day
two
three
second
ta
trial
drugtreat
rat
latenc
day
three
tabl
sinc
earli
report
clark
et
describ
lethal
consequ
buprenorphineinduc
pica
rat
buprenorphin
analgesia
regard
caution
research
laboratori
rat
model
human
diseas
subsequ
report
danger
pica
manag
appropri
husbandri
confirm
present
studi
although
studi
need
regard
safe
use
buprenorphin
analges
strain
rat
data
studi
extend
data
review
guarnieri
et
demonstr
high
safeti
index
buprenorphin
laboratori
anim
medicin
work
also
need
regard
incid
sever
side
effect
buprenorphin
analgesia
deliv
food
ingredi
polym
gelbound
suspens
consensu
rat
treat
safe
acut
dose
extendedreleas
buprenorphin
analgesia
provid
rat
allow
recov
paper
soft
bed
nonetheless
hardwood
bed
standard
mani
facil
inform
need
durat
nausea
differ
strain
sex
analges
procedur
allow
safe
return
rat
standard
husbandri
